Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how TELA Bio turns its OviTex soft-tissue matrix into revenue means wading through pages of FDA trial updates, surgeon adoption metrics, and reimbursement disclosures. Investors hunting for device approval timelines or shifts in R&D spend often find the raw SEC text overwhelming.
With “TELA Bio SEC filings explained simply”, Stock Titan’s AI-powered hub solves that. It reads every “TELA Bio quarterly earnings report 10-Q filing” moments after it hits EDGAR and delivers a plain-English summary of margins, unit volumes, and hospital penetration. Need to see whether executives are buying shares? The platform flags “TELA Bio Form 4 insider transactions real-time” alongside a digest that puts each trade in context. You can jump from an “TELA Bio 8-K material events explained” alert—often new clinical data—to a side-by-side trend chart without opening a PDF.
Below, you’ll find every document type:
- 10-K: Our “TELA Bio annual report 10-K simplified” narrative highlights pipeline milestones, manufacturing capacity, and competitive devices.
- 10-Q: Rapid “TELA Bio earnings report filing analysis” surfaces quarter-over-quarter sales to hospitals and cash burn.
- Form 4: Track “TELA Bio insider trading Form 4 transactions” and “TELA Bio executive stock transactions Form 4” to monitor leadership confidence before catalysts.
- DEF 14A: The “TELA Bio proxy statement executive compensation” breakdown shows how pay aligns with clinical adoption goals.
Whether you’re “understanding TELA Bio SEC documents with AI” for the first time or refining a detailed DCF model, our real-time feeds, concise AI annotations, and expert context turn dense regulatory text into clear insight—so you can focus on evaluating surgical innovation, not searching for it.
Laurence W. Lytton reports beneficial ownership of 3,424,191 shares of TELA Bio common stock, representing 8.5% of the outstanding class based on 39,616,440 shares. The position consists of 2,724,191 shares of common stock and 700,000 shares issuable upon exercise of outstanding warrants. The filing states the reporting person has sole voting power and sole dispositive power over all reported shares.
The filer certified the securities were not acquired to change or influence control of the issuer, indicating this disclosure reflects a substantial passive stake. The inclusion of warrants means the economic exposure and potential future share count may change if those instruments are exercised.
TELA Bio filed a Form S-8 to register 3,500,000 additional shares of common stock under its Amended and Restated 2019 Equity Incentive Plan. The board adopted an amendment and the company’s stockholders approved it, and this filing registers the Additional Shares for issuance under the Amended Equity Plan. After this increase, a total of 7,432,620 shares are registered for issuance under the plan. The filing incorporates prior S-8 registration statements by reference and attaches the Amended Equity Plan and related exhibits.
TELA Bio reported continued commercial growth with revenue of $20.2 million for the quarter ended June 30, 2025, a 26% increase from $16.1 million a year earlier, and $38.7 million for the six months, up 18% year-over-year. Gross profit for the quarter was $14.1 million. Quarterly net loss narrowed to $9.9 million (EPS -$0.22) from $12.6 million, while the six-month net loss was $21.2 million versus $18.3 million, noting the prior-year six-months included a $7.6 million gain on the sale of the NIVIS product line.
Balance sheet and liquidity show $34.98 million in cash and cash equivalents (restricted cash brings cash per statements of cash flows to $35.24 million), total assets of $67.54 million and total liabilities of $58.35 million. The company carries total debt of $41.38 million (long-term portion $38.05 million) under a MidCap term loan maturing in 2027 with covenants including minimum net revenue tests. Product mix for the quarter was $12.49 million OviTex and $7.33 million OviTex PRS, with international sales of $3.0 million. The company discloses an accumulated deficit of $379.9 million and says it expects to incur losses for the foreseeable future.
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.
FAQ
What is the current stock price of Tela Bio (TELA)?
What is the market cap of Tela Bio (TELA)?
